Recombinant peptides in thrombolysis

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 5, 2010, Pages 529-536

  Campbell, Jennifer ^a   Hilleman, Daniel ^b  

^a CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

Author keywords

fibrinolysis; fibrinolytic agents; plasminogen activators; Recombinant peptides; thrombolytic therapy

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RETEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ARTERY DISEASE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; FIBRINOLYTIC THERAPY; HALF LIFE TIME; HEART ARREST; HEART INFARCTION; HUMAN; LIMB ISCHEMIA; LUNG EMBOLISM; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VEIN OCCLUSION; PROCEDURES;

FIBRINOLYTIC AGENTS; HUMANS; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 77954876276     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1255447     Document Type: Review

References (45)

1. Collen D, Lijnen H R. Thrombolytic agents. Thromb Haemost 2005 93 (4) 627-630
2. Todd J L., Tapson V F. Thrombolytic therapy for pulmonary embolism: a critical appraisal. Chest 2009 135 1321-1329
3. Collen D, Lijnen H R. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991 78 (12) 3114-3124
4. Kunamneni A, Abdelghani T TA, Ellaiah P. Streptokinasethe drug of choice for thrombolytic therapy. J Thromb Thrombolysis 2007 23 (1) 9-23
5. Gibler W B. ST-segment elevation myocardial infarction (STEMI): decreasing the time to treatment in the ED. Emergency Medicine Cardiac Research and Education Group. 2007;1:14. Available at: http://www.emcreg.org/pdf/ monographs/Time2Tx.pdf Accessed May 12, 2010
6. Keeley E C., Boura J A., Grines C L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003 361 (9351) 13-20
7. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation 2003 108 (15) 1809-1814
8. Di Mario C, Dudek D, Piscione F et al, CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008 371 (9612) 559-568
9. Cantor W J., Fitchett D, Borgundvaag B et al, TRANSFER-AMI Trial Investigators. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009 360 (26) 2705-2718
10. Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (NORwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010 55 (2) 102-110
11. U.S. Department of Health and Human Services. The Surgeon General's call to action to prevent deep vein thrombosis and pulmonary embolism. 2008. Available at: http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call- to-action-on-dvt-2008.pdf Accessed January 9, 2010
12. Kearon C, Kahn S R., Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 (6, Suppl) 454S-545S (Pubitemid 351892971)
13. Nazir S A., Ganeshan A, Nazir S, Uberoi R. Endovascular treatment options in the management of lower limb deep venous thrombosis. Cardiovasc Intervent Radiol 2009 32 (5) 861-876
14. Chang R, Chen C C., Kam A, Mao E, Shawker T H., Horne M K. III. Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulationresults of pilot study. Radiology 2008 246 (2) 619-629
15. Kahn S R. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis 2006 21 (1) 41-48
16. Arko F R., Davis C M. III, Murphy E H. et al. Aggressive percutaneous mechanical thrombectomy of deep venous thrombosis: early clinical results. Arch Surg 2007 142 (6) 513-518; discussion 518-519
17. Dong B R., Hao Q, Yue J, Wu T, Liu G J. Thrombolytic therapy for pulmonary embolism. Cochrane Database of Systematic Reviews 2009 (3) CD004437
18. Wan S, Quinlan D J., Agnelli G, Eikelboom J W. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004 110 (6) 744-749
19. ClinicalTrials.gov. PEITHO Pulmonary Embolism Thrombolysis Study. Available at: http://clinicaltrials.gov/ct2/show/NCT00639743 Accessed January 11, 2010
20. Albers G W., Amarenco P, Easton J D., Sacco R L., Teal P, American College of Chest Physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 133 (6, Suppl) 630S-669S
21. van den Berg J S., de Jong G. Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital. Acta Neurol Scand 2009 120 (3) 157-160
22. Hacke W, Kaste M, Bluhmki E et al, ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 359 (13) 1317-1329
23. Del Zoppo G J., Saver J L., Jauch E C., Adams H P. Jr, American Heart Association Stroke Council. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009 40 (8) 2945-2948
24. Current Controlled Trials Ltd. The Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke. Available at: http://www.controlled-trials.com/ISRCTN257655182010 Accessed January 3, 2010
25. Gralla J, Brekenfeld C, Arnold M, Schroth G. Acute stroke: present and future of catheter-based interventions. Herz 2008 33 (7) 507-517
26. American Heart Association. Heart disease and stroke statistics: 2009 at-a-glance. 2009. Available at: http://www.americanheart.org/downloadable/ heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009.pdf Accessed January 12, 2010
27. Nichol G, Stiell I G., Laupacis A, Pham B, De Maio V J., Wells G A. A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med 1999 34 (4 Pt 1) 517-525
28. Böttiger B W., Arntz H R., Chamberlain D A. et al, TROICA Trial Investigators European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 2008 359 (25) 2651-2662
29. Böttiger B W., Bode C, Kern S et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001 357 (9268) 1583-1585
30. Hirsch A T., Haskal Z J., Hertzer N R. et al, American Association for Vascular Surgery Society for Vascular Surgery Society for Cardiovascular Angiography and Interventions Society for Vascular Medicine and Biology Society of Interventional Radiology ACC/AHA Task Force on Practice Guidelines Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease American Association of Cardiovascular and Pulmonary Rehabilitation National Heart, Lung, and Blood Institute Society for Vascular Nursing TransAtlantic Inter-Society Consensus Vascular Disease Foundation. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006 113 (11) e463-e654
31. Diffin D C., Kandarpa K. Assessment of peripheral intraarterial thrombolysis versus surgical revascularization in acute lower-limb ischemia: a review of limb-salvage and mortality statistics. J Vasc Interv Radiol 1996 7 (1) 57-63
32. Almahameed A, Bhatt D L. Contemporary management of peripheral arterial disease: III. Endovascular and surgical management. Cleve Clin J Med 2006 73 (suppl 4) S45-S51
33. Ponec D, Irwin D, Haire W D. et al. Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trialthe Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial. J Vasc Interv Radiol 2001 12 (8) 951-955
34. Semba C P., Deitcher S R., Li X, Resnansky L, Tu T, McCluskey E R., Cardiovascular thrombolytic to Open Occluded Lines Investigators. Treatment of occluded central venous catheters with alteplase: results in 1,064 patients. J Vasc Interv Radiol 2002 13 (12) 1199-1205
35. Hilleman D E., Dunlay R W., Packard K A. Reteplase for dysfunctional hemodialysis catheter clearance. Pharmacotherapy 2003 23 (2) 137-141
36. Vogel P M., Bansal V, Marshall M W. Thrombosed hemodialysis grafts: lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device. J Vasc Interv Radiol 2001 12 (10) 1157-1165
37. Clinical pharmacology. Available at: http://www.clinicalpharmacology-ip. com/Default.aspx Accessed January 11, 2010
38. Micromedex healthcare series. Available at: http://www.thomsonhc.com/hcs/ librarian Accessed January 11, 2010
39. Antman E M., Anbe D T., Armstrong P W. et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol 2004 44 (3) E1-E211
40. Grines C L., Westerhausen D R. Jr, Grines L L. et al, Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002 39 (11) 1713-1719
41. Bonnefoy E, Lapostolle F, Leizorovicz A et al, Comparison of Angioplasty and Prehospital Thromboysis in Acute Myocardial Infarction study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002 360 (9336) 825-829 (Pubitemid 35257945)
42. Andersen H R., Nielsen T T., Rasmussen K et al, DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003 349 (8) 733-742
43. Vermeer F, Oude Ophuis A J., vd Berg E J. et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999 82 (4) 426-431
44. Widimský P, Groch L, Zelízko M, Aschermann M, Bednár F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs. immediate thrombolysis vs. combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000 21 (10) 823-831
45. Widimský P, Budesínský T, Vorác D et al, PRAGUE Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trialPRAGUE-2. Eur Heart J 2003 24 (1) 94-104